PMID- 33025622
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20240330
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 203
IP  - 2
DP  - 2021 Feb
TI  - Identification of peripheral CD154(+) T cells and HLA-DRB1 as biomarkers of acute 
      cellular rejection in adult liver transplant recipients.
PG  - 315-328
LID - 10.1111/cei.13533 [doi]
AB  - Decreasing graft rejection and increasing graft and patient survival are great 
      challenges facing liver transplantation (LT). Different T cell subsets 
      participate in the acute cellular rejection (ACR) of the allograft. Cell-mediated 
      immunity markers of the recipient could help to understand the mechanisms 
      underlying acute rejection. This study aimed to analyse different surface 
      antigens on T cells in a cohort of adult liver patients undergoing LT to 
      determine the influence on ACR using multi-parametric flow cytometry functional 
      assay. Thirty patients were monitored at baseline and during 1 year 
      post-transplant. Two groups were established, with (ACR) and without (NACR) acute 
      cellular rejection. Leukocyte, total lymphocyte, percentages of CD4(+) CD154(+) 
      and CD8(+) CD154(+) T cells, human leukocyte antigen (HLA) mismatch between 
      recipient-donor and their relation with ACR as well as the acute rejection 
      frequencies were analysed. T cells were stimulated with concanavalin A (Con-A) 
      and surface antigens were analysed by fluorescence activated cell sorter (FACS) 
      analysis. A high percentage of CD4(+) CD154(+) T cells (P = 0.001) and a low 
      percentage of CD8(+) CD154(+) T cells (P = 0.002) at baseline were statistically 
      significant in ACR. A receiver operating characteristic analysis determined the 
      cut-off values capable to stratify patients at high risk of ACR with high 
      sensitivity and specificity for CD4(+) CD154(+) (P = 0.001) and CD8(+) CD154(+) T 
      cells (P = 0.002). In logistic regression analysis, CD4(+) CD154(+) , CD8(+) 
      CD154(+) and HLA mismatch were confirmed as independent risk factors to ACR. 
      Post-transplant percentages of both T cell subsets were significantly higher in 
      ACR, despite variations compared to pretransplant. These findings support the 
      selection of candidates for LT based on the pretransplant percentages of CD4(+) 
      CD154(+) and CD8(+) CD154(+) T cells in parallel with other transplant factors.
CI  - (c) 2020 British Society for Immunology.
FAU - Boix, F
AU  - Boix F
AUID- ORCID: 0000-0002-3926-7920
AD  - Haematology Service, University Hospital of Salamanca, Research Biomedical 
      Institute of Salamanca (IBSAL), Salamanca, Spain.
FAU - Legaz, I
AU  - Legaz I
AUID- ORCID: 0000-0002-1140-4313
AD  - Department of Legal and Forensic Medicine, Faculty of Medicine, Biomedical 
      Research Institute of Murcia (IMIB), Regional Campus of International Excellence 
      'Campus Mare Nostrum', University of Murcia, Murcia, Spain.
FAU - Minhas, A
AU  - Minhas A
AD  - Clinical Transplantation Laboratory, Barts Health NHS Trust, London, UK.
FAU - Alfaro, R
AU  - Alfaro R
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Jimenez-Coll, V
AU  - Jimenez-Coll V
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Mrowiec, A
AU  - Mrowiec A
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Martinez-Banaclocha, H
AU  - Martinez-Banaclocha H
AUID- ORCID: 0000-0003-4421-4740
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Galian, J A
AU  - Galian JA
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Botella, C
AU  - Botella C
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Moya-Quiles, M R
AU  - Moya-Quiles MR
AUID- ORCID: 0000-0003-3677-6372
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Sanchez-Bueno, F
AU  - Sanchez-Bueno F
AD  - Surgery, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research 
      Institute of Murcia (IMIB), Murcia, Spain.
FAU - Robles, R
AU  - Robles R
AD  - Surgery, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research 
      Institute of Murcia (IMIB), Murcia, Spain.
FAU - de la Pena-Moral, J
AU  - de la Pena-Moral J
AD  - Pathology, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research 
      Institute of Murcia (IMIB), Murcia, Spain.
FAU - Ramirez, P
AU  - Ramirez P
AD  - Surgery, University Clinical Hospital Virgen de la Arrixaca-Biomedical Research 
      Institute of Murcia (IMIB), Murcia, Spain.
FAU - Pons, J A
AU  - Pons JA
AUID- ORCID: 0000-0001-5017-7240
AD  - Digestive Medicine Services, University Clinical Hospital Virgen de la 
      Arrixaca-Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Minguela, A
AU  - Minguela A
AUID- ORCID: 0000-0003-2472-5893
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
FAU - Muro, M
AU  - Muro M
AUID- ORCID: 0000-0001-9987-0994
AD  - Immunology Service, University Clinical Hospital Virgen de la Arrixaca-Biomedical 
      Research Institute of Murcia (IMIB), Murcia, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201029
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Biomarkers)
RN  - 0 (HLA-DRB1 Chains)
RN  - 147205-72-9 (CD40 Ligand)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/*blood
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD40 Ligand/*immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Female
MH  - Flow Cytometry/methods
MH  - Graft Rejection/*immunology
MH  - HLA-DRB1 Chains/*immunology
MH  - Heart Transplantation/methods
MH  - Humans
MH  - Liver Transplantation/methods
MH  - Lymphocyte Activation/immunology
MH  - Male
MH  - Middle Aged
MH  - T-Lymphocyte Subsets/*immunology
MH  - Transplantation, Homologous/methods
MH  - Young Adult
PMC - PMC7806417
OTO - NOTNLM
OT  - CD154+ T cells
OT  - HLA
OT  - acute cellular rejection
OT  - cell-mediated immunity (CMI)
OT  - immunosuppression
OT  - liver transplantation
COIS- Consulting fees and/or non-financial support were reported from Diagnostica 
      Longwood (F. B.), Astellas Pharma S.A. (F. B.) and Rafer (F. B.). The remaining 
      authors certify that they have no competing interests in the subject matter or 
      materials discussed in this manuscript.
EDAT- 2020/10/08 06:00
MHDA- 2021/08/17 06:00
PMCR- 2022/02/01
CRDT- 2020/10/07 05:55
PHST- 2020/06/16 00:00 [received]
PHST- 2020/09/29 00:00 [revised]
PHST- 2020/09/29 00:00 [accepted]
PHST- 2020/10/08 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2020/10/07 05:55 [entrez]
PHST- 2022/02/01 00:00 [pmc-release]
AID - CEI13533 [pii]
AID - 10.1111/cei.13533 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2021 Feb;203(2):315-328. doi: 10.1111/cei.13533. Epub 2020 Oct 
      29.